SCHEMBL5232969

SCHEMBL5232969

CC(=C(C#N)C(N)=S)N1CCCN(c2ccc(Cl)cc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.48
ALDH1A1 P00352 4/20 0.48
KDM4E B2RXH2 3/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
HPGD P15428 2/20 0.48
CHIA Q9BZP6 1/20 0.47
LMNA P02545 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
AKR1C3 P42330 2/20 0.45
HTT P42858 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
POLB P06746 1/20 0.41
MAPK1 P28482 1/20 0.41
GFER P55789 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5232966 1.00 MAPT (0.48) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL5233699 0.95 MAPT (0.52) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL5233716 0.95 MAPT (0.52) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL5233711 0.95 MAPT (0.52) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL5232955 0.88 ALDH1A1 (0.44) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL5229612 0.88 MAPT (0.40) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL5233328 0.88 KDM4E (0.43) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL5229622 0.88 MAPT (0.40) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL5232962 0.88 ALDH1A1 (0.44) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL5233318 0.88 KDM4E (0.43) MAPTALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070219234-A1 Thienopyridine Derivatives SANKYO COMPANY, LIMITED (JP) 2007-09-20 US disclosed
EP-1764367-A1 THIENOPYRIDINE DERIVATIVES Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219234-A1 Thienopyridine Derivatives RASGRP1, NRAS, HRH3 MAPT 4452/4885ALDH1A1 1073/4885KDM4E 1851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.